Inclusion Criteria:

- Age between 18 and 65 years;Genders eligible for study: both;

- Histologic diagnosis of solid malignancies ;

- Performance status of 0 or 1;

- Tumor not amenable to standard curative or palliative therapy;

- life expectancy beyond 3 months;

- Ability to give signed informed consent

Exclusion Criteria:

- Pregnancy or lactation;

- Had a history of brain metastasis or a primary brain tumor;

- An active, potentially severe autoimmune disease;

- Serum creatinine ≥1.5mg/dl or a calculated creatinine clearance ＜60ml/min; WBC count
< 2.0×109/L，hemoglobin < 90g/L，and platelet count < 100×109/L; Total bilirubin value
< 2.0 times the upper limit of normal (ULN), ALT level < 2.0 times ULN, AST < 2.0
times ULN;

- Positive of anti-HIV antibodies;

- An active infection;

- had received chemotherapy or immunotherapy within the prior 4 weeks before study
entry

- Participation in a clinical study during the last 28 days

- QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG